VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: Present and future

Current Cancer Drug Targets

Volumn 11, Issue 5, 2011, Pages 624-653

  Sharma, P S ^a   Sharma, R ^a   Tyagi, T ^a  

^a CSSS (P G) College   (India)

Author keywords

Angiogenesis; Bevacizumab; flk 1; KDR; Sorafenib; Suntinib; Tyrosine kinase; VEGFR

Indexed keywords

2 AMINOBENZAMIDE; 5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; AAL993; ANGIOGENESIS INHIBITOR; AXITINIB; BENZIMIDAZOLE; BRIVANIB; BRIVANIB ALANINATE; CARBAZOLE DERIVATIVE; CEDIRANIB; INDAZOLE DERIVATIVE; INDIRUBIN; INTEDANIB; LINIFANIB; MOTESANIB; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; ORANTINIB; OXINDOLE; PAZOPANIB; PYRIDINE; PYRIMIDINE; QUINAZOLINE; SEMAXANIB; SORAFENIB; SU010382; SUNITINIB; TIVOZANIB; TOCERANIB; TRIAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; AUTOPHOSPHORYLATION; BRAIN TUMOR; BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; CHILDHOOD CANCER; COLON CARCINOMA; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYDROGEN BOND; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHANGIOGENESIS; MELANOMA; MICROVASCULATURE; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; THYROID CANCER; TRANSITIONAL CELL CARCINOMA;

EID: 79958121732     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911795655985     Document Type: Review

References (203)

1. Roskoski, R. Jr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 2007, 62(3), 179-213.
2. Shweiki, D.; Itin, A.; Neufeld, G.; Gitay-Goren, H.; Keshet, E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J. Clin. Invest. 1993, 91(5), 2235-2243.
3. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86 (3), 353-364.
4. Greenblatt, M.; Shubi, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. J. Natl. Cancer Inst. 1968, 41(1), 111-124.
5. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285(21), 1182-1186.
6. Ryu, S.; Albert, D. M. Evaluation of tumor angiogenesis factor with the rabbit cornea model. Invest. Ophthalmol. Vis. Sci. 1979, 18(8), 831-841.
7. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 2002, 29(6), 15-18.
8. Sharma, P. S.; Sharma, R.; Tyagi, T. Receptor tyrosine kinase inhibitors as potent weapons in war against cancers. Curr. Pharm. Des. 2009, 15(7), 758-776.
9. Sharma, P. S.; Sharma, R.; Tyagi, R. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment. Curr. Cancer Drug Targets 2008, 8(1), 53-75.
10. Bergers, G.; Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3(6), 401-410.
11. Bikfalvi, A.; Klein, S.; Pintucci, G.; Rifkin, D.B. Biological roles of fibroblast growth factor-2. Endocr. Rev. 1997, 18(1), 26-45.
12. Simons, M.; Rubanyi, G. M., Eds. Modern concepts in angiogenesis; Imperial College Press: London, 2007.
13. Roy, H.; Bhardwaj, S.; Ylä-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett. 2006, 580(12), 2879-2887.
14. Cui, T. G.; Foster, R. R.; Saleem, M.; Mathieson, P. W.; Gillatt, D. A.; Bates, D. O.; Harper, S. J. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am. J. Physiol. Renal Physiol. 2004, 286(4), F767-73.
15. Roskoski, R. Jr. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem. Biophys. Res. Commun. 2008, 375(3), 287-291.
16. deVries, C.; Escobedo, J. A.; Ueno, H.; Houck, K.; Ferrara, N.; Williams, L. T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992, 255(5047), 989-991.
17. Sato, Y.; Kanno, S.; Oda, N.; Abe, M.; Ito, M.; Shitara, K.; Shibuya, M. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann. N. Y. Acad. Sci. 2000, 902, 201-205.
18. Waltenberger, J.; Claesson-Welsh, L.; Siegbahn, A.; Shibuya, M.; Heldin, C. H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem. 1994, 269(43), 26988-26995.
19. Joukov, V.; Sorsa, T.; Kumar, V.; Jeltsch, M.; Claesson-Welsh, L.; Cao, Y.; Saksela, O.; Kalkkinen, N, Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997, 16(13), 3898-3911.
20. Otrock, Z. K.; Makarem, J. A.; Shamseddine, A. I. Vascular endothelial growth factor family of ligand and receptors. Blood Cells Mol. Dis. 2007, 38, 258-268.
21. Bagri, A.; Tessier-Lavigne, M.; Watts, R. J. Neuropilins in tumor biology. Clin. Cancer Res. 2009, 15(6), 1860-1864.
22. Ellis, L. M. The role of neuropilins in cancer. Mol. Cancer Ther. 2006, 5(5), 1099-1107.
23. Neufeld, G.; Lange, T.; Varshavsky, A.; Kessler, O. Semaphorin signaling in vascular and tumor biology. Adv. Exp. Med. Biol. 2007, 600, 118-131.
24. Figg, W. D.; Folkman, J., Eds. Angiogenesis: An Integrative Approach from Science to Medicine; Springer: New York, 2008.
25. Tortora, G.; Bianco, R.; Daniele, G. Strategies for multiple signaling inhibition. J. Chemother. 2004, 16, 41-43.
26. Griffioen, A. W.; Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52(2), 237-268.
27. Pourgholami, M. H.; Morris, D. L. Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc. Hematol. Agent Med. Chem. 2008, 6(4), 343-347.
28. Karamysheva, A. F. Mechanisms of angiogenesis. Biochemistry (Mosc). 2008, 73(7), 751-762.
29. Yu, J.; Ustach, C.; Kim, H. R. Platelet-derived growth factor signaling and human cancer. J. Biochem. Mol. Biol. 2003, 36(1), 49-59.
30. Augustin, H. G.; Reiss, Y. EphB receptors and ephrinB ligands: regulators of vascular assembly and homeostasis. Cell Tissue Res. 2003, 314(1), 25-31.
31. Acevedo, V. D.; Ittmann, M.; Spencer, D. M. Paths of FGFRdriven tumorigenesis. Cell Cycle 2009, 8(4), 580-588.
32. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307(5706), 58-62.
33. Claes, A.; Leenders, W. Vessel normalization by VEGF inhibition. A complex story. Cancer Biol. Ther. 2008, 7(7), 1014-1016.
34. Cohen, M. H.; Gootenberg, J.; Keegan, P.; Pazdur, R. FDA drug approval summary: Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. The Oncologist 2007, 12(3), 356-361.
35. Veeravagu, A.; Hsu, A. R.; Cai, W.; Hou, L.C.; Tse, V. C.; Chen, X. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat. Anticancer Drug Discov. 2007, 2(1), 59-71.
36. Rossi, A.; Maione, P.; Sacco, P. C.; Falanga, M.; Gridelli, C. Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. Curr. Drug Targets 2010, 11(7), 865-874.
37. Manley, P. W.; Bold, G; Brüggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advanced in the structural biology, design and clinical development of VEGFR kinase inhibitors for treatment of angiogenesis. Biochem. Biophys. Acta 2004, 1697(1-2), 17-27.
38. Lockhart, A. C.; Cropp, G. F.; Berlin, J. D.; Donnelly, E.; Schumaker, R. D.; Schaaf, L. J.; Hande, K. R.; Fleischer, A. C.; Hannah, A. L.; Rothenberg, M. L. Phase I/pilot study of SU5416. [semaxinib] in combination with irrinoteacan/bolus 5-FU/LV in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 2006, 29(2), 109-115.
39. Katanasaka, Y.; Ida, T.; Asai, T.; Shimizu, K.; Koizumi, F.; Maeda, N.; Baba, K.; Oku, N. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1Hpyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett. 2008, 270(2), 260-268.
40. Sistla, A.; Kertelj, A.; Shenoy, N. Development of an intravenous formulation of SU010382 (prodrug of SU5416, an antiangiogenesis agent). PDA J. Pharm. Sci. Technol. 2008, 62(3), 200-210.
41. Kieran, M. W.; Supko, J. G.; Wallace, D.; Fruscio, R.; Poussaint, T. Y.; Phillips, P.; Pollack, I.; Packer, R.; Boyett, J. M.; Blaney, S.; Banerjee, A.; Geyer, R.; Friedman, H.; Goldman, S.; Kun, L. E.; Macdonald, T.; Pediatric Brain Tumor Consortium. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr. Blood Cancer 2009, 52(2), 169-176.
42. Bouérat, L.; Fensholdt, J.; Liang, X.; Havez, S.; Nielsen, S. F.; Hansen, J. R.; Bolvig, S.; Andersson, C. Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis. J. Med. Chem. 2005, 48(17), 5412-5414.
43. Laird, A. D.; Vajkoczy, P.; Shawver, L. K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S. R.; Blake, R. A.; Fong, T. A.; Strawn, L. M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, K. P.; McMahon. G.; Cherrington, J. M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000, 60(15), 4152-4160.
44. Sessa, C.; Viganò, L.; Grasselli, G.; Trigo, J.; Marimon, I.; Lladò, A.; Locatelli, A.; Ielmini, N.; Marsoni, S.; Gianni, L. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur. J. Cancer. 2006, 42(2), 171-178.
45. Tokuyama, J.; Kubota, T.; Saikawa, Y.; Yoshida, M.; Furukawa, T.; Otani, Y.; Kumai, K.; Kitajima, M. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis. Anticancer Res. 2005, 25(1A), 17-22.
46. Klenke, F. M.; Abdollahi, A.; Bertl, E.; Gebhard, M. M.; Ewerbeck, V.; Huber, P. E.; Sckell, A. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007, 7, 49.
47. Naumova, E.; Ubezio, P.; Garofalo, A.; Borsotti, P.; Cassis, L.; Riccardi, E.; Scanziani, E.; Eccles, S. A.; Bani, M. R.; Giavazzi, R. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin. Cancer Res. 2006, 12(6), 1839-1849.
48. Farace, P.; Galiè, M.; Merigo, F.; Daducci, A.; Calderan, L.; Nicolato, E.; Degrassi, A.; Pesenti, E.; Sbarbati, A.; Marzola, P. Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas. Br. J. Cancer 2009, 100(10), 1575-1580.
49. Abrams, T. J.; Lee, J. B.; Murray, L. J.; Pyer, N. K.; Cherrington, J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003, 2(5), 471-478.
50. Mendel, D. B.; Laird, A. D.; Xin, X.; Louie, S. G.; Christensen, J. G.; Li, G.; Schreck, R. E.; Abrams, T. J.; Ngai, T. J.; Lee, L. B.; Murray, L. J.; Carver, J.; Chan, E.; Moss, K. G.; Haznedar, J. O.; Sukbuntherng, J.; Blake, R. A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9(1), 327-337.
51. Heng, D. Y.; Kollmannsberger, C. Sunitinib. Recent Results Cancer Res. 2010, 184, 71-82.
52. Wang, W. L.; Conley, A.; Reynoso, D.; Nolden, L.; Lazar, A. J.; George, S.; Trent, J. C. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother. Pharmacol. 2011, Suppl 1, S15-24.
53. Burstein, H. J.; Elias, A. D.; Rugo, H. S.; Cobleigh, M. A.; Wolff, A. C.; Eisenberg, P. D.; Lehman, M.; Adams, B. J.; Bello, C. L.; DePrimo, S. E.; Baum, C. M.; Miller, K. D. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26(11), 1810-1816.
54. Sonpavde, G.; Jian, W.; Liu, H.; Wu, M. F.; Shen, S. S.; Lerner, S. P. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol. Oncol. 2009, 27(4), 391-399.
55. Casneuf, V. F.; Demetter, P.; Boterberg, T.; Delrue, L.; Peeters, M.; Van Damme, N. Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol. Rep. 2009, 22(1), 105-113.
56. Chow, L. Q.; Eckhardt, S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2007, 25(7), 884-896.
57. deBoüard, S.; Herlin, P.; Christensen, J. G.; Lemoisson, E.; Gauduchon, P.; Raymond, E.; Guillamo, J. S. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro. Oncol. 2007, 9(4), 412-423.
58. Fiedler, W.; Giaccone, G.; Lasch, P.; van der Horst, I.; Brega, N.; Courtney, R.; Abbattista, A.; Shalinsky D. R.; Bokemeyer, C.; Boven E. Phase I trial of SU14813 in patients with advanced solid malignancies. Ann. Oncol. 2011, 22(1), 195-201.
59. Liao, A. T.; Chien, M. B.; Shenoy, N.; Mendel, D. B.; McMahon, G.; Cherrington, J. M.; London, C. A. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100(2), 585-593.
60. Yancey, M. F.; Merritt, D. A.; Lesman, S. P.; Boucher, J. F.; Michels, G. M. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors. J. Vet. Pharmacol. Ther. 2010, 33(2), 162-171.
61. Patel, N.; Sun, L.; Moshinsky, D.; Chen, H.; Leahy, K. M.; Le, P.; Moss, K. G.; Wang, X.; Rice, A.; Tam, D.; Laird, A. D.; Yu, X.; Zhang, Q.; Tang, C.; McMahon, G.; Howlett, A. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability. J. Pharmacol. Exp. Ther. 2003, 306(3), 838-845.
62. Schlessinger, J. SU11248: Genesis of a New Cancer Drug. The Scientist 2005, 19(7), 17.
63. Milker-Zabel, S.; Zabel-du Bois, A.; Ranai, G.; Trinh, T.; Unterberg, A.; Debus, J.; Lipson, K. E.; Abdollahi, A.; Huber, P. E. SU11657 enhances radiosensitivity of human meningioma cells. Int. J. Radiat. Oncol. Biol. Phys. 2008, 70(4), 1213-1218.
64. Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 2009, 52(14), 4466-4480.
65. Stopfer, P.; Rathgen, K.; Bischoff, D.; Lüdtke, S.; Marzin, K.; Kaiser R, Wagner, K.; Ebner T. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica 2011, 41(4), 297-311.
66. Amino, N.; Ideyama, Y.; Yamano, M.; Kuromitsu, S.; Tajinda, K.; Samizu, K.; Hisamichi, H.; Matsuhisa, A.; Shirasuna, K.; Kudoh, M.; Shibasaki, M. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors. Clin. Cancer Res. 2006, 12(5), 1630-1638.
67. Ny, A.; Koch, M.; Vandevelde, W.; Schneider, M.; Fischer, C.; Diez-Juan, A.; Neven, E.; Geudens, I.; Maity, S.; Moons, L.; Plaisance, S.; Lambrechts, D.; Carmeliet, P.; Dewerchin, M. Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood. 2008, 112(5), 1740-1749.
68. Kirkin, V.; Thiele, W.; Baumann, P.; Mazitschek, R.; Rohde, K.; Fellbrich, G.; Weich, H.; Waltenberger, J.; Giannis, A.; Sleeman, J. P. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int. J. Cancer 2004, 112(6), 986-993.
69. rd.; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl] amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 2008, 51(15), 4632-4640.
70. Keisner, S. V.; Shah, S. R. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011, 71(4), 443-454.
71. Bukowski, R. M.; Yasothan, U.; Kirkpatrick, P. Pazopanib. Nat. Rev. Drug Discov. 2010, 9(1), 17-18.
72. Gril, B.; Palmieri, D.; Qian, Y.; Smart, D.; Ileva, L.; Liewehr, D. J.; Steinberg, S. M.; Steeg, P. S. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin. Cancer Res. 2011, 17(1), 142-153.
73. Frey, R. R.; Curtin, M. L.; Albert, D. H.; Glaser, K. B.; Pease, L. J.; Soni, N. B.; Bouska, J. J.; Reuter, D.; Stewart, K. D.; Marcotte, P.; Bukofzer, G.; Li, J.; Davidsen, S. K.; Michaelides, M. R. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem. 2008, 51(13), 3777-3787.
74. Emanuel, S.; Gruninger, R. H.; Fuentes-Pesquera, A.; Connolly, P. J.; Seamon, J. A.; Hazel, S.; Tominovich, R.; Hollister, B.; Napier, C.; D'Andrea, M. R.; Reuman, M.; Bignan, G.; Tuman, R.; Johnson, D.; Moffatt, D.; Batchelor, M.; Foley, A.; O'Connell, J.; Allen, R.; Perry, M.; Jolliffe, L.; Middleton, S. A. A vascular endothelial growth factor receptor-2 kinase inhibitor potentiates the activity of the conventional chemotherapeutic agent's paclitaxel and doxorubicin in tumor xenograft models. Mol. Pharmacol. 2004, 66(3), 635-647.
75. Reuman, M.; Beish, S.; Davis, J.; Batchelor, M. J.; Hutchings, M. C.; Moffat, D. F.; Connolly, P. J.; Russell, R. K. Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasoundmediated addition of MeLi-CeCl3 to a nitrile. J. Org. Chem. 2008, 73(3), 1121-1123.
76. Hughes, T.V.; Emanuel, S. L.; Beck, A. K.; Wetter, S. K.; Connolly, P. J.; Karnachi, P.; Reuman, M.; Seraj, J.; Fuentes-Pesquera, A. R.; Gruninger, R. H.; Middleton, S. A.; Lin, R.; Davis, J. M.; Moffat, D. F. 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 2007, 17(12), 3266-3270.
77. Miyazaki, Y.; Tang, J.; Maeda, Y.; Nakano, M.; Wang, L.; Nolte, R. T.; Sato, H.; Sugai, M.; Okamoto, Y.; Truesdale, A. T.; Hassler, D. F.; Nartey, E. N.; Patrick, D. R.; Ho, M. L.; Ozawa, K. Orally active 4-amino-5-diarylurea-furo[2,3-d]pyrimidine derivatives as anti-angiogenic agent inhibiting VEGFR2 and Tie-2. Bioorg. Med. Chem. Lett. 2007, 17(6), 1773-1778.
78. Miyazaki, Y.; Matsunaga, S.; Tang, J.; Maeda, Y.; Nakano, M.; Philippe, R. J.; Shibahara, M.; Liu, W.; Sato, H.; Wang, L.; Nolte, R. T. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorg. Med. Chem. Lett. 2005, 15(9), 2203-2207.
79. Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Yates, M.; Davidsen, S. K.; Michaelides, M. R. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases. Bioorg. Med. Chem. Lett. 2006, 16(16), 4326-4330.
80. Dai, Y.; Guo, Y.; Frey, R. R.; Ji, Z.; Curtin, M. L.; Ahmed, A. A.; Albert, D. H.; Arnold, L.; Arries, S. S.; Barlozzari, T.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Pease, L. J.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Wishart, N.; Davidsen, S. K.; Michaelides, M. R. Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. J. Med. Chem. 2005, 48(19), 6066-6083.
81. Munchhof, M. J.; Beebe, J. S.; Casavant, J. M.; Cooper, B. A.; Doty, J. L.; Higdon, R. C.; Hillerman, S. M.; Soderstrom, C. I.; Knauth, E. A.; Marx, M. A.; Rossi, A. M.; Sobolov, S. B.; Sun, J. Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity. Bioorg. Med. Chem. Lett. 2004, 14(1), 21-24.
82. McDermott, L. A.; Simcox, M.; Higgins, B.; Nevins, T.; Kolinsky, K.; Smith, M.; Yang, H.; Li, J. K.; Chen, Y.; Ke, J.; Mallalieu, N.; Egan, T.; Kolis, S.; Railkar, A.; Gerber, L.; Luk, K. C. RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. Bioorg. Med. Chem. 2005, 13(16), 4835-4841.
83. McDermott, L. A.; Higgins, B.; Simcox, M.; Luk, K. C.; Nevins, T.; Kolinsky, K.; Smith, M.; Yang, H.; Li, J. K.; Chen, Y.; Ke, J.; Mallalieu, N.; Egan, T.; Kolis, S.; Railkar, A.; Gerber, L.; Liu, J. J.; Konzelmann, F.; Zhang, Z.; Flynn, T.; Morales, O.; Chen, Y. Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg. Med. Chem. Lett. 2006, 16(7), 1950-1953.
84. Guo, X. N.; Zhong, L.; Tan, J. Z.; Li, J.; Luo, X. M.; Jiang, H. L.; Nan, F. J.; Lin, L. P.; Zhang, X. W.; Ding, J. In vitro pharmacological characterization of TKI-28, a broad-spectrum tyrosine kinase inhibitor with anti-tumor and anti-angiogenic effects. Cancer Biol. Ther. 2005, 4(10), 1125-1132.
85. Zhong, L.; Guo, X. N.; Zhang, X. H.; Sun, Q. M.; Tong, L. J.; Wu, Z. X.; Luo, X. M.; Jiang, H. L.; Nan, F. J.; Zhang, X. W.; Lin, L. P.; Ding, J. TKI-31 inhibits angiogenesis by combined suppression signaling pathway of VEGFR2 and PDGFRbeta. Cancer Biol. Ther. 2006, 5(3), 323-330.
86. Huang, S.; Li, R.; Connolly, P. J.; Xu, G.; Gaul, M. D.; Emanuel, S. L.; Lamontagne, K. R.; Greenberger, L M. Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(23), 6063-6066.
87. Huang, S.; Li, R.; Lamontagne, K. R.; Greenberger, L. M.; Connolly, P. J. 4-Aminopyrimidine-5-carbaldehyde oximes as potent VEGFR-2 inhibitors. Part II. Bioorg. Med. Chem. Lett. 2011, 21(6), 1815-1818.
88. Lücking, U.; Siemeister, G.; Schäfer, M.; Briem, H.; Krüger, M.; Lienau, P.; Jautelat, R. Macrocyclic aminopyrimidines as multitarget CDK and VEGF-R inhibitors with potent antiproliferative activities. Chem. Med. Chem. 2007, 2(1), 63-77.
89. Abou El Ella, D. A.; Ghorab, M. M.; Noaman, E.; Heiba, H. I.; Khalil, A. I. Molecular modeling study and synthesis of novel pyrrolo[2,3-d]pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities. Bioorg. Med. Chem. 2008, 16(5), 2391-2402.
90. Dev, I. K.; Dornsife, R. E.; Hopper, T. M.; Onori, J. A.; Miller, C. G.; Harrington, L. E.; Dold, K. M.; Mullin, R. J.; Johnson, J. H.; Crosby, R. M.; Truesdale, A. T.; Epperly, A. H.; Hinkle, K. W.; Cheung, M.; Stafford, J. A.; Luttrell, D. K.; Kumar, R. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumors models. Br. J. Cancer 2004, 91(7), 1391-1398.
91. Bhide, R. S.; Cai, Z. W.; Zhang, Y. Z.; Qian, L.; Wei, D.; Barbosa, S.; Lombardo, L. J.; Borzilleri, R. M.; Zheng, X.; Wu, L. I.; Barrish, J. C.; Kim, S. H.; Leavitt, K.; Mathur, A.; Leith, L.; Chao, S.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R. Sr.; Kukral, D.; Hunt, J. T.; Kamath, A.; Fura, A.; Vyas, V.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Fargnoli, J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f]
92. Ruel, R.; Thibeault, C.; L'Heureux, A.; Martel, A.; Cai, Z. W.; Wei, D.; Qian, L.; Barrish, J. C.; Mathur, A.; D'Arienzo, C.; Hunt, J. T.; Kamath, A.; Marathe, P.; Zhang, Y.; Derbin, G.; Wautlet, B.; Mortillo, S.; Jeyaseelan, R. Sr.; Henley, B.; Tejwani, R.; Bhide, R. S.; Trainor, G. L.; Fargnoli, J.; Lombardo, L. J. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4] triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor. Bioorg. Med. Chem. Lett. 2008, 18(9), 2985-2989.
93. Cai, Z. W.; Zhang, Y.; Borzilleri, R. M.; Qian, L.; Barbosa, S.; Wei, D.; Zheng, X.; Wu, L.; Fan, J.; Shi, Z.; Wautlet, B. S.; Mortillo, S.; Jeyaseelan, R. Sr.; Kukral, D. W.; Kamath, A.; Marathe, P.; D'Arienzo, C.; Derbin, G.; Barrish, J. C.; Robl, J. A.; Hunt, J. T.; Lombardo, L. J.; Fargnoli, J.; Bhide, R. S. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J. Med. Chem. 2008, 51(6), 1976-1980.
94. Palanki, M. S.; Akiyama, H.; Campochiaro, P.; Cao, J.; Chow, C. P.; Dellamary, L.; Doukas, J.; Fine, R.; Gritzen, C.; Hood, J. D.; Hu, S.; Kachi, S.; Kang, X.; Klebansky, B.; Kousba, A.; Lohse, D.; Mak, C. C.; Martin, M.; McPherson, A.; Pathak, V. P.; Renick, J.; Soll, R.; Umeda, N.; Yee, S.; Yokoi, K.; Zeng, B.; Zhu, H.; Noronha, G. Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of agerelated macular degeneration. J. Med. Chem. 2008, 51(6), 1546-1559.
95. Baindur, N.; Chadha, N.; Brandt, B. M.; Asgari, D.; Patch, R. J.; Schalk-Hihi, C.; Carver, T. E.; Petrounia, I. P.; Baumann, C. A.; Ott, H.; Manthey, C.; Springer, B. A.; Player, M. R. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors. J. Med. Chem. 2005, 48(6), 1717-1720.
96. Cai, Z. W.; Wei, D.; Borzilleri, R. M.; Qian, L.; Kamath, A.; Mortillo, S.; Wautlet, B.; Henley, B. J.; Jeyaseelan, R. Sr.; Tokarski, J; Hunt, J. T.; Bhide, R. S.; Fargnoli, J.; Lombardo, L. J. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazinebased VEGFR-2 kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18(4), 1354-1358.
97. Tran, T. C.; Sneed, B.; Haider, J.; Blavo, D.; White, A.; Aiyejorun, T.; Baranowski, T. C.; Rubinstein, A. L.; Doan, T. N.; Dingledine, R.; Sandberg, E. M. Quantitative screening assay for antiangiogenic compounds using transgenic zebra fish. Cancer Res. 2007, 67(23), 11386-11392.
98. Whittles, C. E.; Pocock, T. M.; Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Harper, S. J.; Bates, D. O. ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Microcirculation 2002, 9(6), 513-522.
99. Xiao, Z.; Kong, Y.; Yang, S.; Li, M.; Wen, J.; Li, L. Upregulation of Flk-1 by bFGF via the ERK pathway is essential for VEGFmediated promotion of neural stem cell proliferation. Cell Res. 2007, 17(1), 73-79.
100. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Curwen, J. O.; Hennequin, L. F.; Thomas, A. P.; Stokes, E. S.; Curry, B.; Richmond, G. H.; Wadsworth, P. F. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000, 60(4), 970-975.
101. Nguyen, Q. D.; Rodrigues, S.; Rodrigue, C. M.; Rivat, C.; Grijelmo, C.; Bruyneel, E.; Emami, S.; Attoub, S.; Gespach, C. Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts. Mol. Cancer Ther. 2006, 5(8), 2070-2077.
102. Gaballah, K.; Oakley, R.; Hills, A.; Ryan, A.; Partridge, M. The antiangiogenic agent ZD4190 prevents tumor outgrowth in a model of minimal residual carcinoma in deep tissues. Br. J. Cancer. 2009, 101(3), 418-423.
103. Hennequin, L. F.; Stokes, E. S.; Thomas, A. P.; Johnstone, C.; Plé, P. A.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Kendrew, J.; Curwen, J. O. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 2002, 45(6), 1300-1312.
104. Yiin, J. J.; Hu, B.; Schornack, P. A.; Sengar, R. S.; Liu, K. W.; Feng, H.; Lieberman, F. S.; Chiou, S. H.; Sarkaria, J. N.; Wiener, E. C.; Ma, H. I.; Cheng, S. Y. ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. Mol. Cancer Ther. 2010, 9(4), 929-941.
105. Morabito, A.; Piccirillo, M. C.; Falasconi, F.; DeFeo, G.; DelGiudice, A.; Bryce, J.; DiMaio. M.; DeMaio. E.; Normanno, N.; Perrone, F. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009, 14(4), 378-390.
106. Natale, R. B.; Bodkin, D.; Govindan, R.; Sleckman, B. G.; Rizvi, N. A.; Capó, A.; Germonpré, P.; Eberhardt, W. E.; Stockman, P. K.; Kennedy, S. J.; Ranson, M. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J. Clin. Oncol. 2009, 27(15), 2523-2529.
107. Wedge, S. R.; Kendrew, J.; Hennequin, L. F.; Valentine, P. J.; Barry, S. T.; Brave, S. R.; Smith, N. R.; James, N. H.; Dukes, M.; Curwen, J. O.; Chester, R.; Jackson, J. A.; Boffey, S. J.; Kilburn, L. L.; Barnett, S.; Richmond, G. H.; Wadsworth, P. F.; Walker, M.; Bigley, A. L.; Taylor, S. T.; Cooper, L.; Beckm, S.; Jürgensmeier, J. M.; Ogilvie, D. J. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005, 65(10), 4389-4400.
108. Heckman, C. A.; Holopainen, T.; Wirzenius, M.; Keskitalo, S.; Jeltsch, M.; Ylä-Herttuala, S.; Wedge, S. R.; Jürgensmeier, J. M.; Alitalo, K. The tyrosine kinase inhibitor cediranib blocks ligandinduced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68(12), 4754-4762.
109. van Cruijsen, H.; Voest, E. E.; Punt, C. J.; Hoekman, K.; Witteveen, P. O.; Meijerink, M. R.; Puchalski, T. A.; Robertson, J.; Saunders, O.; Jürgensmeier, J. M.; van Herpen, C. M.; Giaccone, G. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur. J. Cancer 2010, 46(5), 901-911.
110. Nakamura, K.; Yamamoto, A.; Kamishohara, M.; Takahashi, K.; Taguchi, E.; Miura, T.; Kubo, K.; Shibuya, M.; Isoe, T. KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol. Cancer Ther. 2004, 3(12), 1639-1649.
111. Matsunaga, N.; Nakamura, K.; Yamamoto, A.; Taguchi, E.; Tsunoda, H.; Takahashi, K. Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. Mol. Cancer Ther. 2006, 5(1), 80-88.
112. Wissner, A.; Fraser, H. L.; Ingalls, C. L.; Dushin, R. G.; Floyd, M. B.; Cheung, K.; Nittoli, T.; Ravi, M. R.; Tan, X.; Loganzo, F. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg. Med. Chem. 2007, 15(11), 3635-3648.
113. Fraley, M. E.; Arrington, K. L.; Buser, C. A.; Ciecko, P. A.; Coll, K. E.; Fernandes, C.; Hartman, G. D.; Hoffman, W. F.; Lynch, J. J.; McFall, R. C.; Rickert, K.; Singh, R.; Smith, S.; Thomas, K. A.; Wong, B. K. Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors, effects of 5-amido-and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding. Bioorg. Med. Chem. Lett. 2004, 14(2), 351-355.
114. Kubo, K.; Shimizu, T.; Ohyama, S.; Murooka, H.; Iwai, A.; Nakamura, K.; Hasegawa, K.; Kobayashi, Y.; Takahashi, N.; Takahashi, K.; Kato, S.; Izawa, T.; Isoe, T. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of Nphenyl-N'-{4-(4-quinolyloxy)phenyl}ureas. J. Med. Chem. 2005, 48(5), 1359-1366.
115. Sharma, B. K.; Sharma, S. K.; Singh, P.; Sharma, S. A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFRalpha tyrosine kinase inhibitors: derivatives of N-phenyl-N'-{4-(4-quinolyloxy) phenyl} urea as antitumor agents. J. Enzyme Inhib. Med. Chem. 2008, 23(2), 168-173.
116. Nakamura, K.; Taguchi, E.; Miura, T.; Yamamoto, A.; Takahashi, K.; Bichat, F.; Guilbaud, N.; Hasegawa, K.; Kubo, K.; Fujiwara, Y.; Suzuki, R.; Kubo, K.; Shibuya, M.; Isae, T. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006, 66(18), 9134-9142.
117. De Luca, A.; Normanno, N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs 2010, 13(9), 636-645.
118. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R. A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006, 5(10), 835-844.
119. Liu, L.; Cao, Y.; Chen, C.; Zhang, X.; McNabola, A.; Wilkie, D.; Wilhelm, S.; Lynch, M.; Carter, C. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66(24), 11851-11858.
120. Takezawa, K.; Okamoto, I.; Yonesaka, K.; Hatashita, E.; Yamada, Y.; Fukuoka, M.; Nakagawa, K. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells. Cancer Res. 2009, 69(16), 6515-6521.
121. Hasskarl, J. Sorafenib. Recent Results Cancer Res. 2010, 184, 61-70.
122. Claridge, S.; Raeppel, F.; Granger, M. C.; Bernstein, N.; Saavedra, O.; Zhan, L.; Llewellyn, D.; Wahhab, A.; Deziel, R.; Rahil, J.; Beaulieu, N.; Nguyen, H.; Dupont, I.; Barsalou, A.; Beaulieu, C.; Chute, I.; Gravel, S.; Robert, M. F.; Lefebvre, S.; Dubay, M.; Pascal, R.; Gillespie, J.; Jin, Z.; Wang, J.; Besterman, J. M.; MacLeod, A. R.; Vaisburg, A. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg. Med. Chem. Lett. 2008, 18(9), 2793-2798.
123. Dai, Y.; Hartandi, K.; Soni, N. B.; Pease, L. J.; Reuter, D. R.; Olson, A. M; Osterling, D. J.; Doktor, S. Z.; Albert, D. H.; Bouska, J. J.; Glaser, K. B.; Marcotte, P. A.; Stewart, K. D.; Davidsen, S. K.; Michaelides, M. R. Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18(1), 386-390.
124. Azad, A.; Herbertson, R. A.; Pook, D.; White, S.; Mitchell, P. L.; Tebbutt, N. C. Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncol. 2009, 48(4), 619-621.
125. Polverino, A.; Coxon, A.; Starnes, C.; Diaz, Z.; DeMelfi, T.; Wang, L.; Bready, J.; Estrada, J.; Cattley, R.; Kaufman, S.; Chen, D.; Gan, Y.; Kumar, G.; Meyer, J.; Neervannan, S.; Alva, G.; Talvenheimo, J.; Montestruque, S.; Tasker, A.; Patel, V.; Radinsky, R.; Kendall, R. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006, 66(17), 8715-8721.
126. Caenepeel, S.; Renshaw-Gegg, L.; Baher, A.; Bush, T. L.; Baron, W.; Juan, T.; Manoukian, R.; Tasker, A. S.; Polverino, A.; Hughes, P. E. Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. J. Exp. Clin. Cancer Res. 2010, 29, 96.
127. Coxon, A; Bush, T.; Saffran, D.; Kaufman, S.; Belmontes, B.; Rex, K.; Hughes, P.; Caenepeel, S.; Rottman, J. B.; Tasker, A.; Patel, V.; Kendall, R.; Radinsky, R.; Polverino, A. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin. Cancer Res. 2009, 15(1), 110-118.
128. Kiselyov, A. S.; Semenova, M.; Semenov, V. V.; Milligan, D. inhibitors of VEGF receptors-1 and-2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg. Med. Chem. Lett. 2006, 16(7), 1913-1919.
129. Bilodeau, M. T.; Balitza, A. E.; Koester, T. J.; Manley, P. J.; Rodman, L. D.; Buser-Doepner, C.; Coll, K. E.; Fernandes, C.; Gibbs, J. B.; Heimbrook, D. C.; Huckle, W. R.; Kohl, N.; Lynch, J. J.; Mao, X.; McFall, R. C.; McLoughlin, D.; Miller-Stein, C. M.; Rickert, K. W.; Sepp-Lorenzino, L.; Shipman, J. M.; Subramanian, R.; Thomas, K. A.; Wong, B. K.; Yu, S.; Hartman, G. D. Potent N-(1, 3-thiazol-2-yl) pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channel. J. Med. Chem. 2004, 47(25), 6363-6372.
130. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rösel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factorinduced responses and tumor growth after oral administration. Cancer Res. 2000, 60(8), 2178-2189.
131. Joensuu, H.; DeBraud, F.; Coco, P.; DePas, T.; Putzu, C.; Spreafico, C.; Bono, P.; Bosselli, S.; Jalava, T.; Lauret, D.; Casali, P. G. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann. Oncol. 2008, 19(1), 173-177.
132. Scott, E. N.; Meinhardt, G.; Jacques, C.; Laurent, D.; Thomas, A. L. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumors. Expert Opin. Investig. Drugs 2007, 16(3), 367-379.
133. Banerjee, S.; A'Hern, R.; Detre, S.; Littlewood-Evans, A. J.; Evans, D. B.; Dowsett, M.; Martin, L. A.; Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin. Cancer Res. 2010, 16(16), 4178-4187.
134. Duncton, M. A.; Piatnitski Chekler, E. L.; Katoch-Rouse, R.; Sherman, D.; Wong, W. C.; Smith, L. M.; Kawakami, J. K.; Kiselyov, A. S.; Milligan, D. L.; Balagtas, C.; Hadari, Y. R.; Wang, Y.; Patel, S. N.; Rolster, R. L.; Tonra, J. R.; Surguladze, D.; Mitelman, S.; Kussie, P.; Bohlen, P.; Doody, J. F. Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. Bioorg. Med. Chem. 2009, 17(2), 731-740.
135. Kiselyov, A. S.; Semenov, V. V.; Milligan, D. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II. Chem. Biol. Drug Des. 2006, 68(6), 308-313.
136. Kiselyov, A. S.; Semenova, M.; Semenov, V. V.; Piatnitski, E. L. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II. Chem. Biol. Drug Des. 2006, 68(5), 250-255.
137. Wang, F. E.; Shi, G.; Niesman, M. R.; Rewolinski, D. A.; Miller, S. S. Receptor tyrosine kinase inhibitors AG013764 and AG013711 reduce choroidal neovascularization in rat eye. Exp. Eye Res. 2007, 84(5), 922-933.
138. Zhou, J.; Goh, B. C.; Albert, D. H.; Chen, C. S. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J. Hematol. Oncol. 2009, 2, 33.
139. Dai, Y.; Hartandi, K.; Ji, Z.; Ahmed, A. A.; Albert, D. H.; Bauch, J. L.; Bouska, J. J.; Bousquet, P. F.; Cunha, G. A.; Glaser, K. B.; Harris, C. M.; Hickman, D.; Guo, J.; Li, J.; Marcotte, P. A.; Marsh, K. C.; Moskey, M. D.; Martin, R. L.; Olson, A. M.; Osterling, D. J.; Pease, L. J.; Soni, N. B.; Stewart, K. D.; Stoll, V. S.; Tapang, P.; Reuter, D. R.; Davidsen, S. K.; Michaelides, M. R. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl) urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J. Med. Chem. 2007, 50(7), 1584-1597.
140. Albert, D. H.; Tapang, P.; Magoc, T. J.; Pease, L. J.; Reuter, D. R.; Wei, R. Q.; Li, J.; Guo, J.; Bousquet, P. F.; Ghoreishi-Haack, N. S.; Wang, B.; Bukofzer, G. T.; Wang, Y. C.; Stavropoulos, J. A.; Hartandi, K.; Niquette, A. L.; Soni, N.; Johnson, E. F.; McCall, J. O.; Bouska, J. J.; Luo, Y.; Donawho, C. K.; Dai, Y.; Marcotte, P.A.; Glaser, K. B.; Michaelides, M. R.; Davidsen, S. K. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5(4), 995-1006.
141. Sharma, S.; Abhyankar, V.; Burgess, R. E.; Infante, J.; Trowbridge, R. C.; Tarazi, J.; Kim, S.; Tortorici, M.; Chen, Y.; Robles, R. L. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann. Oncol. 2010, 21(2), 297-304.
142. Hu-Lowe, D. D.; Zou, H. Y.; Grazzini, M. L.; Hallin, M. E.; Wickman, G. R.; Amundson, K.; Chen, J. H.; Rewolinski, D. A.; Yamazaki, S.; Wu, E. Y.; McTigue, M. A.; Murray, B. W.; Kania, R. S.; O'Connor, P.; Shalinsky, D. R.; Bender, S. L. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 2008, 14(22), 7272-7283.
143. Cohen, E. E.; Rosen, L. S.; Vokes, E. E.; Kies, M. S.; Forastiere, A. A.; Worden, F. P.; Kane, M. A.; Sherman, E.; Kim, S.; Bycott, P.; Tortorici, M.; Shalinsky, D. R.; Liau, K. F.; Cohen, R. B. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J. Clin. Oncol. 2008, 26(29), 4708-4713.
144. Schiller, J. H.; Larson, T.; Ou, S. H.; Limentani, S.; Sandler, A.; Vokes, E.; Kim, S.; Liau, K.; Bycott, P.; Olszanski, A. J.; von Pawel. J. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J. Clin. Oncol. 2009, 27(23), 3836-3841.
145. Gingrich, D. E.; Reddy, D. R.; Iqbal, M. A.; Singh, J.; Aimone, L. D.; Angeles, T. S.; Albom, M.; Yang, S.; Ator, M. A.; Meyer, S. L.; Robinson, C.; Ruggeri, B. A.; Dionne, C. A.; Vaught, J. L; Mallamo, J. P.; Hudkins, R. L. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. J. Med. Chem. 2003, 46(25), 5375-5388.
146. Ruggeri, B.; Singh, J.; Gingrich, D.; Angeles, T.; Albom, M.; Yang, S.; Chang, H.; Robinson, C.; Hunter, K.; Dobrzanski, P.; Jones-Bolin, S.; Pritchard, S.; Aimone, L.; Klein-Szanto, A.; Herbert, J. M.; Bono, F.; Schaeffer, P.; Casellas, P.; Bourie, B.; Pili, R.; Isaacs, J.; Ator, M.; Hudkins, R.; Vaught, J.; Mallamo, J.; Dionne, C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 2003, 63(18), 5978-5991.
147. Jones-Bolin, S.; Zhao, H.; Hunter, K.; Klein-Szanto, A.; Ruggeri, B. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol. Cancer Ther. 2006, 5(7), 1744-1753.
148. Becknell, N. C.; Zulli, A. L.; Angeles, T. S.; Yang, S.; Albom, M. S.; Aimone, L. D.; Robinson, C.; Chang, H.; Hudkins, R. L. Novel C-3 N-urea, amide, and carbamate dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole analogs as potent TIE-2 and VEGFR-2 dual inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(20), 5368-5372.
149. Dandu, R.; Zulli, A. L.; Bacon.; E. R.; Underiner, T.; Robinson, C.; Chang, H.; Miknyoczki, S.; Grobelny, J.; Ruggeri, B. A.; Yang, S.; Albom, M. S.; Angeles, T. S.; Aimone, L. D.; Hudkins, R. L. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGFR-2 receptor tyrosine kinases. Bioorg. Med. Chem. Lett. 2008, 18(6), 1916-1921.
150. Lee, S. H.; Lopes de Menezes, D.; Vora, J.; Harris, A.; Ye, H.; Nordahl, L.; Garrett, E.; Samara, E.; Aukerman, S. L.; Gelb, A. B.; Heise, C. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res. 2005, 11(10), 3633-3641.
151. Sarker, D.; Molife, R.; Evans, T. R.; Hardie, M.; Marriott, C.; Butzberger-Zimmerli, P.; Morrison, R.; Fox, J. A.; Heise, C.; Louie, S.; Aziz, N.; Garzon, F.; Michelson, G.; Judson, I. R.; Jadayel, D.; Braendle, E. de Bono, J. S. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14(7), 2075-2081.
152. Potashman, M. H.; Bready, J.; Coxon, A.; DeMelfi, T. M. Jr.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmange, J. C.; Kaufman, S. A.; Kendall, R.; Kim, J. L.; Kumar, G. N.; Long, A. M.; Neervannan, S.; Patel, V. F.; Polverino, A.; Rose, P.; Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. J. Med. Chem. 2007, 50(18), 4351-4373.
153. Borzilleri, R. M.; Bhide, R. S.; Barrish, J. C.; D'Arienzo, C. J.; Derbin, G. M.; Fargnoli, J.; Hunt, J. T.; Jeyaseelan, R. Sr.; Kamath, A.; Kukral, D. W.; Marathe, P.; Mortillo, S.; Qian, L.; Tokarski, J. S.; Wautlet, B. S.; Zheng, X.; Lombardo, L. J. Discovery and evaluation of N-cyclopropyl-2, 4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. J. Med. Chem. 2006, 49(13), 3766-3769.
154. Beebe J, S.; Jani, J. P.; Knauth, E.; Goodwin, P.; Higdon, C.; Rossi, A. M.; Emerson, E.; Finkelstein, M.; Floyd, E.; Harriman, S.; Atherton, J.; Hillerman, S.; Soderstrom, C.; Kou, K.; Gant, T.; Noe, M. C.; Foster, B.; Rastinejad, F.; Marx, M. A.; Schaeffer, T.; Whalen, P. M.; Roberts, W. G. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003, 63(21), 7301-7309.
155. Cohen, R. B.; Langer, C. J.; Simon, G. R.; Eisenberg, P. D.; Hainsworth, J. D.; Madajewicz, S.; Cosgriff, T. M.; Pierce, K.; Xu, H.; Liau, K.; Healey, D. A phase I/randomized phase II, noncomparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother. Pharmacol. 2007, 60(1), 81-89.
156. Kiselyov, A. S.; Semenova, M.; Semenov, V.V. 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2. Bioorg. Med. Chem. Lett. 2009, 19(4), 1195-1198.
157. rd.; Brown, M. L.; Veal, J. M.; Nolte, R. T.; Wang, L.; Liu, W.; Crosby, R. M.; Johnson, J. H.; Epperly, A. H.; Kumar, R.; Luttrell, D. K.; Stafford, J. A. Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J. Med. Chem. 2005, 48(5), 1610-1619.
158. Kiselyov, A. S.; Piatnitski, E.; Milligan, D.; Ouyang, X. 1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2. Chem. Biol. Drug Des. 2007, 69(5), 331-337.
159. Kiselyov, A. S.; Semenova, M.; Semenov, V. V.; Piatnitski, E.; Ouyang, S. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. Bioorg. Med. Chem. Lett. 2006, 16(5), 1440-1444.
160. Manley, P. W.; Furet, P.; Bold, G.; Brüggen, J.; Mestan, J.; Meyer, T.; Schnell, C. R.; Wood, J.; Haberey, M.; Huth, A.; Krüger, M.; Menrad, A.; Ottow, E.; Seidelmann, D.; Siemeister, G.; Thierauch, K. H. Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J. Med. Chem. 2002, 45(26), 5687-5693.
161. Manley, P. W.; Bold, G.; Brüggen, J.; Fendrich, G.; Furet, P.; Mestan, J.; Schnell, C.; Stolz, B.; Meyer, T.; Meyhack, B.; Stark, W.; Strauss, A.; Wood, J. Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochem. Biophys. Acta 2004, 1697(1-2), 17-27.
162. Garton, A. J.; Crew, A. P.; Franklin, M.; Cooke, A. R.; Wynne, G. M.; Castaldo, L.; Kahler, J.; Winski, S. L.; Franks, A.; Brown, E. N.; Bittner, M. A.; Keily, J. F.; Briner, P.; Hidden, C.; Srebernak, M. C.; Pirrit, C.; O'Connor, M.; Chan, A.; Vulevic, B.; Henninger, D.; Hart, K.; Sennello, R.; Li, A. H.; Zhang, T.; Richardson, F.; Emerson, D. L.; Castelhano, A. L.; Arnold, L. D.; Gibson, N. W. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res. 2006, 66(2), 1015-1024.
163. Lin H. L.; Zhang, H.; Medower, C.; Hollenberg, P. F.; Johnson, W. W. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug. Drug. Metab. Dispos. 2011, 39(2), 345-350.
164. Matsui, J.; Yamamoto, Y.; Funahashi, Y.; Tsuruoka, A.; Watanabe, T.; Wakabayashi, T.; Uenaka, T.; Asada, M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 2008, 122(3), 664-671.
165. Matsui, J.; Funahashi, Y.; Uenaka, T.; Watanabe, T.; Tsuruoka, A.; Asada, M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008, 14(17), 5459-5465.
166. D'Amato, R. J.; Loughnan, M. S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 1994, 91(9), 4082-4085.
167. Melchert, M.; List, A. The thalidomide saga. Int. J. Biochem. Cell Biol. 2007, 39(7-8), 1489-99.
168. Aragon-Ching, J. B.; Dahut, W. L. VEGF Inhibitors and Prostate Cancer Therapy. Curr. Mol. Pharmacol. 2009, 2(2), 161-168.
169. Kraemer, A.; Hauser, S.; Kim, Y.; Gorschlüter, M.; Müller, S. C.; Brossart, P.; Schmidt-Wolf, I. G. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Ger. Med. Sci. 2009, 7, Doc04.
170. Zhang, J.; Zhang, Y.; Zhang, S.; Wang, S.; He, L. Discovery of novel taspine derivatives as antiangiogenic agent. Bioorg. Med. Chem. Lett. 2010, 20(2), 718-721.
171. Gautier, B.; Goncalves, V.; Diana, D.; Di Stasi, R.; Teillet, F.; Lenoir, C.; Huguenot, F.; Garbay, C.; Fattorusso, R,; D'Andrea, L. D.; Vidal, M.; Inguimbert, N. Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J. Med. Chem. 2010, 53(11), 4428-4440.
172. Cebulla, C. M.; Jockovich, M. E.; Boutrid, H.; Piña, Y.; Ruggeri, M.; Jiao, S.; Bhattacharya, S. K.; Feuer, W. J.; Murray, T. G. Lack of Effect of SU1498, an Inhibitor of Vascular Endothelial Growth Factor Receptor-2, in a Transgenic Murine Model of Retinoblastoma. Open Ophthalmol. J. 2008, 2, 62-7.
173. Hos, D.; Bock, F.; Dietrich, T.; Onderka, J.; Kruse, F. E.; Thierauch, K. H.; Cursiefen, C. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest. Ophthalmol. Vis. Sci. 2008, 49(5), 1836-1842.
174. Wissner, A.; Floyd, M. B.; Johnson, B. D.; Fraser, H.; Ingalls, C.; Nittoli, T.; Dushin, R. G.; Discafani, C.; Nilakantan, R.; Marini, J.; Ravi, M.; Cheung, K.; Tan, X.; Musto, S.; Annable, T.; Siegel, M. M.; Loganzo, F. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. J. Med. Chem. 2005, 48(24), 7560-75681.
175. Curtin, M. L.; Frey, R. R.; Heyman, H. R.; Sarris, K. A.; Steinman, D. H.; Holmes, J. H.; Bousquet, P. F.; Cunha, G. A.; Moskey, M. D.; Ahmed, A. A.; Pease, L. J.; Glaser, K. B.; Stewart, K. D.; Davidsen, S. K.; Michaelides, M. R. Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14(17), 4505-4509.
176. Heyman, H. R.; Frey, R. R.; Bousquet, P. F.; Cunha, G. A.; Moskey, M. D.; Ahmed, A. A.; Soni, N. B.; Marcotte, P. A.; Pease, L. J.; Glaser, K. B.; Yates, M.; Bouska, J. J.; Albert, D. H.; Black-Schaefer, C. L.; Dandliker, P. J.; Stewart, K. D.; Rafferty, P.; Davidsen, S. K.; Michaelides, M. R.; Curtin, M. L. Thienopyridine urea inhibitors of KDR kinase. Bioorg. Med. Chem. Lett. 2007, 17(5), 1246-1249.
177. Hasegawa, M.; Nishigaki, N.; Washio, Y.; Kano, K.; Harris, P. A.; Sato, H.; Mori, I.; West, R. I.; Shibahara, M.; Toyoda, H.; Wang, L.; Nolte, R. T.; Veal, J. M.; Cheung, M. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J. Med. Chem. 2007, 50(18), 4453-44570.
178. Thompson, A. M.; Delaney, A. M.; Hamby, J. M.; Schroeder, M. C.; Spoon, T. A.; Crean, S. M.; Showalter, H. D.; Denny, W. A. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases. J. Med. Chem. 2005, 48(14), 4628-4653.
179. Uno, M.; Ban, H. S.; Nabeyama, W.; Nakamura, H. de novo design and synthesis of N-benzylanilines as new candidates for VEGFR tyrosine kinase inhibitors. Org. Biomol. Chem. 2008, 6(6), 979-981.
180. Dominguez, C.; Smith, L.; Huang, Q.; Yuan, C.; Ouyang, X.; Cai, L.; Chen, P.; Kim, J.; Harvey, T.; Syed, R.; Kim, T. S.; Tasker, A.; Wang, L.; Zhang, M.; Coxon, A.; Bready, J.; Starnes, C.; Chen, D.; Gan, Y.; Neervannan, S.; Kumar, G.; Polverino, A.; Kendall, R. Discovery of N-phenyl nicotinamides as potent inhibitors of KDR. Bioorg. Med. Chem. Lett. 2007, 17(21), 6003-6008.
181. Harmangem, J. C.; Weiss, M. M.; Germain, J.; Polverino, A. J.; Borg, G.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T.; DiPietro, L.; Doerr, N.; Estrada, J.; Flynn, J.; Graceffa, R. F.; Harriman, S. P.; Kaufman, S.; La, D. S.; Long, A.; Martin, M. W.; Neervannan, S.; Patel, V. F.; Potashman, M.; Regal, K.; Roveto, P. M.; Schrag, M. L.; Starnes, C.; Tasker, A.; Teffera, Y.; Wang, L.; White, R. D.; Whittington, D. A.; Zanon, R. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J. Med. Chem. 2008, 51(6), 1649-1667.
182. Weiss, M. M.; Harmange, J. C.; Polverino, A. J.; Bauer, D.; Berry, L.; Berry, V.; Borg, G.; Bready, J.; Chen, D.; Choquette, D.; Coxon, A.; DeMelfi, T.; Doerr, N.; Estrada, J.; Flynn, J.; Graceffa, R. F.; Harriman, S. P.; Kaufman, S.; La, D. S.; Long, A.; Neervannan, S.; Patel, V. F.; Potashman, M.; Regal, K.; Roveto, P. M.; Schrag, M. L.; Starnes, C.; Tasker, A.; Teffera, Y.; Whittington, D. A.; Zanon, R. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. J. Med. Chem. 2008, 51(6), 1668-1680.
183. La, D. S.; Belzile, J.; Bready, J. V.; Coxon, A.; DeMelfi, T.; Doerr, N.; Estrada, J.; Flynn, J. C.; Flynn, S. R.; Graceffa, R. F.; Harriman, S. P.; Larrow, J. F.; Long, A. M.; Martin, M. W.; Morrison, M. J.; Patel, V. F.; Roveto, P. M.; Wang, L.; Weiss, M. M.; Whittington, D. A.; Teffera, Y.; Zhao, Z.; Polverino, A. J.; Harmange, J. C. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. J. Med. Chem. 2008, 51(6), 1695-1705.
184. Kiselyov, A. S.; Milligan, D.; Ouyang, X. Novel inhibitors of VEGF receptors-1 and-2 based on azole-5-carboxamide templates. Bioorg. Med. Chem. Lett. 2007, 17(13), 3550-3557.
185. Kiselyov, A. S.; Piatnitski, E.; Semenova M.; Semenov, V. V. N-(Aryl)-4-(azolylethyl) thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. Bioorg. Med. Chem. Lett. 2006, 16(3), 602-606.
186. Raeppel, S.; Claridge, S.; Saavedra, O.; Gaudette, F.; Zhan, L.; Mannion, M.; Zhou, N.; Raeppel, F.; Granger, M. C.; Isakovic, L.; Déziel, R.; Nguyen, H.; Beaulieu, N.; Beaulieu, C.; Dupont, I.; Robert, M. F.; Lefebvre, S.; Dubay, M.; Rahil, J.; Wang, J.; Ste-Croix, H.; Robert, Macleod. A.; Besterman, J.; Vaisburg, A. N-(3-fluoro-4-(2-arylthieno [3, 2-b] pyridin-7-yloxy) phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: A novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19(5), 1323-1328.
187. Lee, K. I.; Park, Y.; Park, S. J.; Hwang, J. H.; Lee, S. J.; Kim, G. D.; Park, W. K.; Lee, S.; Jeong, D.; Kong, J. Y.; Kang, H. K.; Cho, H. Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases. Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases. Bioorg. Med. Chem. Lett. 2006, 16(3), 737-742.
188. Yu, H.; Wang, Z.; Zhang, L.; Zhang, J.; Huang, Q. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies. Chem. Biol. Drug Des. 2007, 69(3), 204-211.
189. Latreille, J.; Batist. G.; Laberge, F.; Champagne, P.; Croteau, D.; Falardeau, P.; Levinton, C.; Hariton, C.; Evans, W. K.; Dupont, E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 2003, 4(4), 231-236.
190. Lee, S. Y.; Chung, S. M. Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression. Vascul. Pharmacol. 2007, 47(5-6), 313-318.
191. Katzel, J. A.; Fanucchi, M. P.; Li, Z. Recent advances of novel targeted therapy in non-small cell lung cancer. J. Hematol. Oncol. 2009, 2, 2.
192. Horn, L.; Sandler, A. B. Angiogenesis in the treatment of nonsmall cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6(2), 206-217.
193. LaMontagne, K. R.; Butler, J.; Borowski, V. B.; Fuentes-Pesquera, A. R.; Blevitt, J. M.; Huang, S.; Li, R.; Connolly, P. J.; Greenberger, L. M. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo. Angiogenesis 2009, 12(3), 287-296.
194. Gaudette, F.; Raeppel, S.; Nguyen, H.; Beaulieu, N.; Beaulieu, C.; Dupont, I.; Macleod, A. R.; Besterman, J. M.; Vaisburg, A. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere head groups. Bioorg. Med. Chem. Lett. 2010, 20(3), 848-852.
195. Kirkali, Z. What is new in kidney cancer? Expert. Rev. Anticancer Ther. 2009, 9(12), 1753-1755.
196. Presta, L. G.; Chen, H.; O'Connor, S. J.; Chisholm, V.; Meng, Y. G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997, 57(20), 4593-4599.
197. Rotsos, T. G.; Moschos, M. M. Cystoid macular edema. Clin. Ophthalmol. 2008, 2(4), 919-930.
198. Horn, L.; Sandler, A. B. Angiogenesis in the treatment of nonsmall cell lung cancer. Proc. Am. Thorac. Soc. 2009, 6(2), 206-217.
199. Cheng, J. W.; Wei, R. L. Ranibizumab for age-related macular degeneration. N. Engl. J. Med. 2011, 364(6), 582.
200. Rodriguez-Fontal, M.; Alfaro, V.; Kerrison, J. B.; Jablon, E. P. Ranibizumab for diabetic retinopathy. Curr. Diabetes Rev. 2009, 5(1), 47-51.
201. Posey, J. A.; Ng, T. C.; Yang, B.; Khazaeli, M. B.; Carpenter, M. D.; Fox, F.; Needle, M.; Waksal, H.; LoBuglio, A. F. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. 2003, 9(4), 1323-1332.
202. Spratlin, J. Ramucirumab (IMC-1121B): monoclonal antibody inhibition of vascular endothelial growth factor receptor-2. Curr. Oncol. Rep. 2011, 13(2), 97-102.
203. Spratlin, J. L.; Cohen, R.B.; Eadens, M.; Gore, L.; Camidge, D. R.; Diab, S.; Leong, S.; O'Bryant, C.; Chow, L. Q.; Serkova, N. J.; Meropol, N. J.; Lewis, N. L.; Chiorean, E. G.; Fox, F.; Youssoufian, H.; Rowinsky, E. K.; Eckhardt, S. G. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 2010, 28(5), 780-787.